导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.66% | 1828/4345 |
| 近一周 | -1.79% | 2545/4962 |
| 近一月 | -9.02% | 4665/4922 |
| 近一季 | -20.94% | 4516/4747 |
| 近半年 | -1.72% | 1709/4477 |
| 近一年 | 6.27% | 1462/4016 |
| 近两年 | 121.04% | 378/2712 |
| 近三年 | 77.92% | 236/2054 |
| 成立以来 | -30.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.49% 2322/4961 |
36.84% 881/5312 |
- - |
- - |
| 2025 | 54.47% 355/4813 |
-3.40% 3051/3635 |
3.80% 944/4076 |
55.35% 183/4524 |
-0.83% 2671/4813 |
| 2024 | 20.68% 447/3463 |
-1.70% 1264/2808 |
-6.36% 1925/3014 |
30.96% 119/3129 |
0.11% 1266/3463 |
| 2023 | -23.06% 1948/2656 |
-0.86% 1831/2280 |
-8.02% 1948/2385 |
-10.08% 1947/2515 |
-6.18% 1657/2655 |
| 2022 | -28.29% 1544/2207 |
-19.15% 1436/1919 |
6.37% 715/2016 |
-18.85% 1740/2113 |
2.76% 843/2208 |
| 2021 | 16.04% 282/1822 |
-5.97% 969/1255 |
30.28% 40/1330 |
-6.43% 928/1466 |
1.24% 976/1822 |
| 2020 | 82.47% 36/1250 |
4.59% 68/1022 |
33.55% 27/1060 |
9.62% 632/1152 |
- - |
| 2019 | 47.53% 120/1092 |
32.98% 148/748 |
-10.18% 716/797 |
7.88% 75/844 |
14.49% 20/912 |
| 2018 | -33.50% 554/834 |
- - |
- - |
- - |
-13.87% 561/691 |
| 2017 | -30.77% 591/714 |
- - |
- - |
- - |
- - |
| 2016 | -31.81% 508/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安创业板50指数A VS. 长安沪深300非周期A(740101) |